Related Experiment Video
Updated: Feb 15, 2026
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
CERA Attenuates Kidney Fibrogenesis in the db/db Mouse by Influencing the Renal Myofibroblast Generation
Christin Fischer1, Natalie Deininger2, Gunter Wolf3
1Department of Internal Medicine III, University Hospital Jena, Am Klinikum 1, D-07747 Jena, Germany. fischer.christin@uni-jena.de.
Abstract:
Tubulointerstitial fibrosis (TIF) is a pivotal pathophysiological process in patients with diabetic nephropathy (DN). Multiple profibrotic factors and cell types, including transforming growth factor beta 1 (TGF-β1) and interstitial myofibroblasts, respectively, are responsible for the accumulation of extracellular matrix in the kidney. Matrix-producing myofibroblasts can originate from different sources and different mechanisms are involved in the activation process of the myofibroblasts in the fibrotic kidney. In this study, 16-week-old db/db mice, a model for type 2 DN, were treated for two weeks with continuous erythropoietin receptor activator (CERA), a synthetic erythropoietin variant with possible non-hematopoietic, tissue-protective effects. Non-diabetic and diabetic mice treated with placebo were used as controls. The effects of CERA on tubulointerstitial fibrosis (TIF) as well as on the generation of the matrix-producing myofibroblasts were evaluated by morphological, immunohistochemical, and molecular biological methods. The placebo-treated diabetic mice showed significant signs of beginning renal TIF (shown by picrosirius red staining; increased connective tissue growth factor (CTGF), fibronectin and collagen I deposition; upregulated KIM1 expression) together with an increased number of interstitial myofibroblasts (shown by different mesenchymal markers), while kidneys from diabetic mice treated with CERA revealed less TIF and fewer myofibroblasts. The mechanisms, in which CERA acts as an anti-fibrotic agent/drug, seem to be multifaceted: first, CERA inhibits the generation of matrix-producing myofibroblasts and second, CERA increases the ability for tissue repair. Many of these CERA effects can be explained by the finding that CERA inhibits the renal expression of the cytokine TGF-β1.
Insights
Continuous erythropoietin receptor activator (CERA) reduces tubulointerstitial fibrosis (TIF) in diabetic nephropathy (DN) mice by inhibiting myofibroblast generation and decreasing transforming growth factor beta 1 (TGF-β1) expression, promoting kidney repair.
Area of Science:
- Nephrology
- Diabetology
- Pharmacology
Background:
- Diabetic nephropathy (DN) is characterized by tubulointerstitial fibrosis (TIF), driven by profibrotic factors like transforming growth factor beta 1 (TGF-β1) and interstitial myofibroblasts.
- Myofibroblast activation and extracellular matrix accumulation are key processes in kidney fibrosis.
- Continuous erythropoietin receptor activator (CERA), a synthetic erythropoietin, may possess non-hematopoietic, tissue-protective effects.
Purpose of the Study:
- To investigate the effects of CERA on tubulointerstitial fibrosis (TIF) in a mouse model of type 2 diabetic nephropathy (DN).
- To evaluate CERA's impact on the generation of matrix-producing myofibroblasts in the fibrotic kidney.
- To elucidate the mechanisms underlying CERA's potential anti-fibrotic actions.
Main Methods:
- Treatment of 16-week-old db/db mice (type 2 DN model) with CERA for two weeks.
- Use of non-diabetic and placebo-treated diabetic mice as controls.
- Assessment of TIF and myofibroblast populations using morphological, immunohistochemical, and molecular biological methods.
Main Results:
- Diabetic mice showed significant renal TIF, increased connective tissue growth factor (CTGF), fibronectin, collagen I, and KIM1 expression, along with more interstitial myofibroblasts.
- CERA treatment in diabetic mice resulted in reduced TIF and fewer myofibroblasts compared to placebo-treated controls.
- CERA treatment was associated with decreased renal expression of TGF-β1.
Conclusions:
- CERA demonstrates anti-fibrotic effects in diabetic nephropathy by inhibiting myofibroblast generation and potentially enhancing tissue repair.
- The observed benefits of CERA are linked to its ability to inhibit renal TGF-β1 expression.
- CERA represents a potential therapeutic agent for mitigating tubulointerstitial fibrosis in diabetic kidney disease.
Related Concept Videos
01:45Kidney Structure
02:42Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...